drugset / Trial / NCT01989455

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

NCT01989455

Phase 1 Completed 64 enrolled ApoPharma
RandomizedParallel-groupQuadruple-blind

Summary

Single center, randomized, double-blind, placebo-controlled, adaptive sequential ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of single doses of deferiprone administered by intravenous infusion to healthy males and females. A bioavailability comparison will be included.

Timeline

Start
2013-11
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 500 mg Intravenous
Subject Deferiprone Small molecule 1000 mg Intravenous
Subject Deferiprone Small molecule 1500 mg Intravenous
Subject Deferiprone Small molecule 2000 mg Intravenous

Indications

No indication recorded.